Key result
Antiplatelet therapy in hemodialysis increases bleeding risk and impairs vascular access longevity without preventing thrombosis.
Why the study?
Studies on antiplatelet medications evaluating bleeding risk and vascular access outcomes in hemodialysis patients have produced inconsistent results.
Do antiplatelet medications improve vascular access patency without significantly increasing bleeding risk in hemodialysis patients?
Systematic Review (n=26,476)
Do antiplatelet medications improve vascular access patency without significantly increasing bleeding risk in hemodialysis patients?
While antiplatelet medications are frequently prescribed to maintain vascular access in hemodialysis patients, their use must be carefully weighed against the heightened risk of bleeding and potential negative impacts on access longevity.
Answers are grounded in this paper and cite their sources.
Requires individualized risk-benefit assessment in hemodialysis; challenges routine antiplatelet use for access patency and supports targeted trials.
Background: Vascular access failure is a common complication seen among hemodialysis (HD) patients. Antiplatelet (AP) medications are often prescribed to help reduce thrombosis and increase vascular access patency. Studies on AP agents evaluating the bleeding risk for HD patients have produced inconsistent results. We aimed to investigate the utilization of AP medications among patients who undergo hemodialysis (HD). We performed a systematic review and meta-analysis of observational studies on AP medicaations used in HD therapy. Methods: This systematic review used Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 as standards. Inclusion criteria for literature eligibility are full-text literature, written in english, and published between 2014 and 2024. Exclusion criteria used for this study were editorials, review articles and identical journal that has been published, and submissions without DOI. Literatures were collected from online reference sources like Pubmed and SagePub. Result: In the PubMed database, the results of our search brought up 23 articles, whereas the results of our search on SagePub brought up 19 articles. The results of the search conducted for the last year of 2014 yielded a total 9 articles for PubMed and 5 articles for SagePub. In the end, we compiled a total of 5 papers, 4 of which came from PubMed and 1 of which came from SagePub. We included five research that met the criteria. Conclusion: AP medications are given in HD patients with high cardiovascular commorbidities to increase vascular patency and prevent thrombosis. Aspirin and P2Y12 inhibitors (PI) such as clopidogrel are commonly used. AP medications might cause shortened longevity of AV access for HD patients. The benefits of AP therapy for cardiovascular protection needs to be evaluated along with its possible effect on AVG outcomes.
No takes yet. Share an insight, caveat, or question.
Giovani et al. (2024) conducted a systematic review in Hemodialysis (n=26,476). Antiplatelet medications vs. No antiplatelet therapy was evaluated. Antiplatelet medications in hemodialysis patients may increase the risk of bleeding and shorten the longevity of arteriovenous access without consistently preventing recurrent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: